Rimgaile Urbaityte

Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment–Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2019 · 212 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Abacavir Use and Risk for Myocardial Infarction and Cardiovascular Events: Pooled Analysis of Data From Clinical Trials

Cassandra Nan, Mark S. Shaefer, Rimgaile Urbaityte et al. · Open Forum Infectious Diseases · 2018 · 42 citations · Full text

Medicine, Cardiology, Pharmacotherapy +14

Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis

Joseph J. Eron, Chien‐Ching Hung, Jean‐Guy Baril et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 2020 · 18 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Durable Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI Studies

Pedro Cahn, Juan Sierra Madero, José Ramón Arribas et al. · Journal of Infection and Public Health · 2020 · 16 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Improvements in Patient-Reported Outcomes After 12 Months of Maintenance Therapy With Cabotegravir + Rilpivirine Long-Acting Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide in the Phase 3b SOLAR Study

Cristina Mussini, Charles Cazanave, Eisuke Adachi et al. · AIDS and Behavior · 2024 · 16 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17